SCHEMBL28059059

SCHEMBL28059059

Oc1ccnc(N2CCCCC2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.47
CDC7 O00311 1/20 0.47
ACHE P22303 3/20 0.46
CCNT1 O60563 2/20 0.44
CCNA2 P20248 2/20 0.44
CDK2 P24941 2/20 0.44
CDK9 P50750 2/20 0.44
DYRK1A Q13627 2/20 0.43
POLB P06746 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
GBA1 P04062 1/20 0.42
ALDH1A1 P00352 3/20 0.41
HTT P42858 2/20 0.41
MEN1 O00255 1/20 0.41
TSHR P16473 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
GAA P10253 1/20 0.41
PIK3CA P42336 1/20 0.40
ADRB1 P08588 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18228033 0.98 ACHE (0.47) MAPK8CDC7ACHECCNT1CCNA2
SCHEMBL28059058 0.94 DYRK1A (0.44) MAPK8CDC7ACHECCNT1CCNA2
SCHEMBL11113279 0.81 ACHE (0.51) ACHECCNT1CCNA2CDK2CDK9
SCHEMBL11113633 0.81 ADRB1 (0.61) ACHESMN1; SMN2ALDH1A1ADRB1KDM4E
SCHEMBL5525967 0.81 PIK3CA (0.58) ACHECCNT1CCNA2CDK2CDK9
SCHEMBL30635502 0.80 GBA1 (0.55) MAPK8CDC7ACHECCNT1CCNA2
SCHEMBL27941842 0.80 GBA1 (0.55) MAPK8CDC7ACHECCNT1CCNA2
SCHEMBL12597157 0.78 KDM4E (0.55) ACHEPOLBSMN1; SMN2ALDH1A1TSHR
SCHEMBL7019990 0.78 ACHE (0.45) MAPK8CDC7ACHECCNT1CCNA2
SCHEMBL9900073 0.78 KDM1A (0.47) MAPK8CDC7ACHECCNT1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250084054-A1 SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION JNANA THERAPEUTICS INC. 2025-03-13 US disclosed
CN-105814051-B Tetrahydroimidazopyridine derivatives as modulators of TNF activity UCB生物制药私人有限公司 2018-09-25 CN disclosed
CN-107787319-A Indazole derivatives as modulators of TNF activity UCB生物制药私人有限公司 2018-03-09 CN disclosed
CN-104470924-B Imidazopyrazines derivant as TNF active regulator UCB生物制药私人有限公司 2016-11-09 CN disclosed
CN-105814041-A Benzotriazole derivatives as modulators of TNF activity UCB生物制药私人有限公司 2016-07-27 CN disclosed
CN-105814056-A Purine derivatives as modulators of TNF activity UCB生物制药私人有限公司 2016-07-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250084054-A1 SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION SLC18A2, SLC6A19, SLC1A1 MAPK8 3748/4885CDC7 2669/4885ACHE 4763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.